Centessa Pharmaceuticals PLC at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) TranscriptMar 31, 2022- Centessa Pharmaceuticals PLC -To Discuss ZF874 Phase 1 Part B results in Alpha-1 Antitrypsin Deficiency TranscriptNov 01, 2021
- Centessa Pharmaceuticals PLC Discuss Topline Data from Proof-of-Concept Study of SerpinPC Trial Call TranscriptSep 09, 2021
Centessa Pharmaceuticals PLC Discuss Topline Data from Proof-of-Concept Study of SerpinPC Trial Call Transcript
Good morning, everyone. We are pleased you can join us today for the announcement of topline data from our Phase 2a trial of SerpinPC in hemophilia A and hemophilia B patients. Please refer to our press release from this morning as well as the corresponding data presentation. Both of which are available on our website.
During this call, we will be making forward-looking statements. These statements include without limitation, discussions of the open label extension study of SerpinPC and its design and conduct, plans for continued development of SerpinPC including our global development plan and registrational path for this candidate, our expectations with respect to the treatment paradigm for hemophilia A and B and our ability to deliver impactful medicines to patients.
Such statements reflect our current views, estimates and projections only as of today and are subject to a number of risks and uncertainties that could cost actual results to differ materially and adversely from those implied by such forward-looking statements. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
